Bonfante V, Bonadonna G, Villani F, Di Fronzo G, Martini A, Casazza A M
Cancer Treat Rep. 1979 May;63(5):915-8.
A phase I study of 4'-epi-Adriamycin (4'-epi-ADM) was performed in 22 patients with various types of advanced solid tumors. Very preliminary results would indicate that the drug produces a pattern of acute toxicity which is similar to that of Adriamycin. However, the incidence of vomiting, alopecia, and marrow suppression was less pronounced than that of Adriamycin. 4'-Epi-ADM prolonged the systolic time interval, although no patient presented clinical signs of cardiotoxicity. Two patients with renal carcinoma and malignant melanoma showed objective improvement. Present results suggest that further clinical studies with 4'-epi-ADM are indicated.
对22例不同类型的晚期实体瘤患者进行了4'-表阿霉素（4'-epi-ADM）的I期研究。非常初步的结果表明，该药物产生的急性毒性模式与阿霉素相似。然而，呕吐、脱发和骨髓抑制的发生率比阿霉素低。4'-表阿霉素延长了收缩期时间间期，尽管没有患者出现心脏毒性的临床症状。两名肾癌和恶性黑色素瘤患者显示出客观缓解。目前的结果表明，有必要对4'-表阿霉素进行进一步的临床研究。
